News

TumorCube, a New Unit within DiscoveryBioMed, Will Use 3D Biogel-based Platforms to Perform 384-Well Plate-based Bioassays and 3D Bioreactor-driven Studies to Discover, Validate and Profile Anti-cancer Therapeutics on Human Cancer Cells

DiscoveryBioMed, Inc. (DBM, www.discoverybiomed.com) announces a new unit of its contract research organization (CRO) services business called TumorCube that is formed based upon our growing expertise in 3D Biogel-driven bioassays on diseased and normal human cell platform technologies. A trademark application has been filed. "DBM has a growing CRO services business in 3D Biogel-driven bioassays of diseased and normal human kidney cells. It is showcased prominently on our website, and we are proud to have many biotechnology companies and BioPharmaceutical organizations globally as our clients," explained Dr. Erik Schwiebert, Ph.D., CEO of DBM. "We have now extended those offerings to include the assay of human urological cancers and endocrine-driven cancers such as ovarian cancers and breast cancers." DBM is also assessing the feasibility of our 3D platforms for the assay of neurological and other cancers at present. DBM is utilizing existing human cancer cell lines in our initial technology optimization. "Interestingly, diseased human kidney cells and existing human cancer cell lines respond differently to specific lead therapeutic drugs or industry standard anti-cancer drugs when grown in...

Read More

Introducing SENTIRIX, a New CRO Unit of DiscoveryBioMed focused on Taste Profiling

SENTIRIX, a New DiscoveryBioMed Unit Working With Monell Center Licensed Technology, Will Implement Human Taste Bud Cell Platform Technologies as a Valuable Screening and Profiling Tool for the Food, Beverage, Flavor & BioPharmaceutical Marketplaces DiscoveryBioMed, Inc. (DBM, www.discoverybiomed.com) announces a new unit of its contract research organization (CRO) services business called Sentirix formed based upon our continuing 5-year collaboration with world-renowned, Philadelphia-based Monell Chemical Senses Center. "The name, Sentirix, is derived from the Latin word sentire ‘to feel in a sensory way,’" explained Dr. Erik Schwiebert, Ph.D., CEO of DBM. "Our logo showcases the name and illustrates a taste bud with a tastant molecule binding to the pore of the taste bud." A trademark application has been filed. Sentirix aims to provide the most relevant model of human taste sensory pathways for the purpose of understanding taste sensation, characterizing taste profiles of pharmaceuticals and food ingredients, and identifying naturally-derived taste modulators. Specifically, Sentirix uses human taste bud epithelial cell (hTBEC) platform technologies developed by DBM from the prior patented work of Drs. Hakan Ozdener and Nancy Rawson at Monell....

Read More

DiscoveryBioMed and Monell Chemical Senses Center Awarded $1.68 Million Small Business Grant to Profile Bitter Taste Blockers

Collaboration Will Screen Human Taste Bud Cells with Small Molecule Libraries to Develop Easier Ways for Children and Adults to Take Bitter-Tasting Medications (Birmingham, AL) - DiscoveryBioMed, Inc. (DBM) has been awarded nearly $1.7 million over the next two years by the National Institutes of Health’s Small Business Technology Transfer Research (STTR) program to find bitter taste blockers to improve medication compliance. This STTR award is administered by the National Institute on Deafness and Other Communication Disorders (NIDCD) within the National Institutes of Health. Philadelphia-based Monell Chemical Senses Center is a long-time DBM collaborator. The new funds continue their five-year relationship to advance Monell’s proprietary human taste-cell technology to discover taste modulators. Building on their successful creation of bitter-responsive human taste bud epithelial cell (hTBECs) lines with earlier funding, this industry-academic partnership’s Phase 2 STTR is aimed at discovering bitter blockers, small molecules combined with bitter medicines and bitter-tasting foods to improve their taste. “We are humbled and honored to receive this continued funding from NIDCD,” said Dr. Erik Schwiebert, CEO and CSO of DBM....

Read More

DiscoveryBioMed, Inc. and the Monell Chemical Senses Center deepen their scientific collaboration fueled by human taste bud epithelial cell platform technologies

Begun in late 2015, DiscoveryBioMed, Inc. and the Monell Chemical Senses Center (www.monell.org) are collaborating on transforming a Monell invention of isolating primary cultures of human taste bud cells into applied science platforms with which to interrogate human taste sensory pathways and with which to utilize in taste modulator discovery campaigns. Some highlights of this synergistic commercial-academic collaboration are listed below: DBM optimized the culture, cryopreservation and immortalization of human taste bud epithelial cells (hTBECs) for greater utility in taste modulator discovery programs.DBM established a method to isolate and establish hTBEC cultures from the taste bud tissue of individual donors – this method allows the hTBEC cell behavior to be directly linked to the donor’s taste behavior and to the donor’s taste genetics.Using magnetic immunocapture methods and traditional cloning, DBM and Monell established sweet-responsive hTBEC cell lines and cultures for future use.With funding from the Bill and Melinda Gates Foundation, Monell and DBM performed bitter taste assays on bitter-tasting medicines given to pediatric populations in the developing world for malaria, parasitism, HIV/AIDS and other ailments...

Read More

DiscoveryBioMed, Inc., Nitor Therapeutics and Therachem Medilabs are collaborating on a Phase 1 SBIR-driven humanized drug discovery program discovering and validating STING inhibitors for niche autoimmune diseases

Three local biotechnology companies are collaborating on a new humanized drug discovery campaign to discover inhibitor of STING, a protein known as stimulator of interferon genes. Dr. Shanta Bantia, Nitor Therapeutics’ President and CEO, approached DBM about this drug target for niche autoimmune diseases. She, together with DBM’s Dr. John Streiff and Erik Schwiebert, designed a Critical Path of discovery and validation assays using human cells to garner Phase 1 SBIR funding from the NIH NIAID. In addition to DBM and Nitor, Dr. Pooran Chand, President of Therachem Medilabs, has opened a new site in Birmingham, and is assisting this project with medicinal chemistry and synthetic chemistry expertise. “STING and its associated signaling pathway is an exciting drug target in BioPharmaceutical circles at present,” declared Dr. Shanta Bantia. “There have already been multiple deals between smaller biotechnology firms and larger BioPharmaceutical companies for STING agonists and antagonists. We seek to join this sector and we believe that our approach is novel. We are already discovering novel hit-to-lead chemical classes that are STING inhibitors and we...

Read More

Dr. Grace Salzer, Ph.D. has joined DBM as a Principal Scientist

DiscoveryBioMed, Inc. is pleased to announce that Dr. Grace Salzer has joined DBM as a principal scientist. “We continue to find wonderful, young and energetic talent from the University of Alabama at Birmingham, “ explained Dr. Erik Schwiebert, DBM’s CEO and CSO. “Newly minted Ph.D. scientists can work independently and can wear multiple hats, something critical to our scientific teams and programs at DBM. Grace is the latest key hire for us and she will work on the formation of two new scientific units within DBM’s CRO services business.” Grace completed her Ph.D. in 2019 from UAB in work focused on sudden cardiac rhythm arrest and the role of pannexins, extracellular purinergic signaling, and calcium channels and transporters in the heart. DBM will have more news updates regarding new sectors of its CRO services business in the coming months.

Read More